BACKGROUND Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma(PSC),a rare,previously rapidly fatal subtype of nonsmall-cell lung cancer.CASE SUMMARY We report the case of a 69-...BACKGROUND Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma(PSC),a rare,previously rapidly fatal subtype of nonsmall-cell lung cancer.CASE SUMMARY We report the case of a 69-year-old man presented with respiratory distress caused by a large left upper lung lobe mass diagnosed as PSC with programmed death-ligand 1 expressed on more than 50 percent of tumor cells.The patient was started on pembrolizumab and,after 5 cycles,there was a more than 80 percent decrease in the size of the tumor mass.Further decrease was seen at the end of 10 cycles.The patient has been tolerating pembrolizumab well,with no limiting side-effects.Fourteen months after first coming into the hospital,he remains asymptomatic.CONCLUSION Pembrolizumab appears as a viable emerging treatment for PSC.展开更多
B 细胞特异的莫洛尼白血病毒插入位点1（Bmi-1）基因是多梳基因家族的核心成员之一，被认为是一种原癌基因，在细胞的自我更新、增殖及凋亡方面发挥重要作用。研究证实，Bmi-1的高表达与非小细胞肺癌的发生、发展、侵袭及预后密切相关。...B 细胞特异的莫洛尼白血病毒插入位点1（Bmi-1）基因是多梳基因家族的核心成员之一，被认为是一种原癌基因，在细胞的自我更新、增殖及凋亡方面发挥重要作用。研究证实，Bmi-1的高表达与非小细胞肺癌的发生、发展、侵袭及预后密切相关。Bmi-1基因有望成为一种新的肿瘤分子标志物，为非小细胞肺癌的诊断、靶向治疗提供新的方向。展开更多
文摘BACKGROUND Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma(PSC),a rare,previously rapidly fatal subtype of nonsmall-cell lung cancer.CASE SUMMARY We report the case of a 69-year-old man presented with respiratory distress caused by a large left upper lung lobe mass diagnosed as PSC with programmed death-ligand 1 expressed on more than 50 percent of tumor cells.The patient was started on pembrolizumab and,after 5 cycles,there was a more than 80 percent decrease in the size of the tumor mass.Further decrease was seen at the end of 10 cycles.The patient has been tolerating pembrolizumab well,with no limiting side-effects.Fourteen months after first coming into the hospital,he remains asymptomatic.CONCLUSION Pembrolizumab appears as a viable emerging treatment for PSC.
